Clinical trial
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496
Study timeline
Study start (actual)2022-04-19Date precision: day
Registry last updated2025-10-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Castration-Resistant Prostatic Cancerunresolved
Malignant Melanomaunresolved
Pancreatic Ductal Carcinomaunresolved
Hepatocellular Cancerunresolved
Epithelial Ovarian Cancerunresolved
Renal Cell Carcinomaunresolved
Interventions
vobramitamab duocarmazineBIOLOGICAL
lorigerlimabBIOLOGICAL
Sponsors & collaborators
MacroGenicslead sponsor
Mapped research locations
New YorkNew York, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1AtlantaGeorgia, United States1San FranciscoCalifornia, United States1PittsburghPennsylvania, United States1Oklahoma CityOklahoma, United States1CharlottesvilleVirginia, United States1SarasotaFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05293496 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.